Novo's innovation hunter brings back abandoned project

A new collaboration to identify small molecules against diabetes and secondary complications provides the framework for Novo Nordisk's future bet on oral drugs based on small molecules - a research field the company originally gave up in 2007.

Photo: Novo Nordisk

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles